COMPANY INFO
Dash Bio, officially known as Dash Bio, Inc., was founded in 2024 by Ander Tallett and Dave Johnson. It is a seed-stage biotechnology company based in Boston, Massachusetts, with 2-10 employees, operating an automated clinical bioanalysis platform that leverages AI and robotics to accelerate drug development by delivering high-quality assays with faster turnaround times than traditional methods. The company's website is www.dash.bio, and it operates in the biotechnology and pharmaceutical research industry.
Dash Bio is a pioneering seed-stage biotechnology company based in Boston, Massachusetts, specializing in automated clinical bioanalysis powered by AI and robotics. Founded in 2024, Dash Bio accelerates drug development for pharmaceutical research through rapid, high-quality assays and an advanced, AI-driven laboratory platform.
The Dash Bio leadership team consists of seasoned experts in biotechnology, artificial intelligence, laboratory automation, product development, and finance. Their collective backgrounds span executive roles at industry leaders like Moderna, Benchling, and Ginkgo Bioworks, as well as deep experience in building early-stage startups and managing high-growth biotech ventures. The company’s management team is distinguished by strengths in data-driven decision-making, operational excellence, and a shared commitment to redefining clinical bioanalysis.
As Co-founder & CEO, Dave Johnson drives Dash Bio’s strategic vision, building and scaling the company’s AI-driven automation platform for clinical bioanalysis. Dave Johnson has led major initiatives including securing $6.5M in seed funding, launching Dash Bio’s automated, GLP-compliant laboratory, and forging early partnerships in the biotechnology sector. His impact is reflected in the rapid rollout of Dash Bio’s services and the company’s establishment as a credible, innovative force in AI-powered drug development.
Dave Johnson holds a PhD in Biomedical Science from University at Albany, SUNY, and a BS in Biology from University of Vermont. Previously, he served as Chief Data & AI Officer and VP of Informatics at Moderna, where he built out transformative digital and AI infrastructure for clinical research. His extensive expertise in bioinformatics and AI deeply informs his approach to the Dash Bio CEO role, positioning the company at the forefront of tech-enabled pharmaceutical research.
As COO, Ander Tallett orchestrates Dash Bio’s lab operations, infrastructure scale-up, and seamless integration of robotics and AI systems into clinical bioanalysis workflows. Ander Tallett has optimized operational processes, built robust lab infrastructure, and ensured high-throughput quality, all supporting Dash Bio’s mission to deliver rapid, reliable assays to clients.
Prior to co-founding Dash Bio, Ander Tallett was CEO & Founder of DigitalRadius and held senior operational roles at Moderna. With an MBA from Wharton School and a BS in Chemical Engineering from MIT, he brings a pragmatic, cross-disciplinary approach to scaling biotech operations and has deep experience driving innovation in life sciences startups.
As CTO, Ely Porter spearheads platform technology for Dash Bio, developing core AI models, robotic integrations, and the software backbone for automated assay delivery. Ely Porter’s leadership has been pivotal in enabling real-time data analytics and robust lab management systems that set Dash Bio apart from traditional bioanalysis providers.
Ely Porter holds a PhD in Molecular Biology from University of Colorado Boulder and a BS in Biochemistry from University of Florida. He previously co-founded RootPath, managing technology development for synthetic biology and automation. Ely’s expertise in synthetic immunology and bioinformatics underpins Dash Bio’s technical prowess and innovation in healthcare discovery tools.
As investor representative and advisor, Maria Palma provides strategic guidance on AI and biotech integration for Dash Bio, supporting the company’s ambitious product roadmap and market expansion initiatives. Her contributions help shape executive strategy and build networks across the biotech and pharmaceutical sectors.
Maria Palma is a General Partner at Freestyle Capital, with a BA in Economics from UC Berkeley and prior experience at Khosla Ventures. Known for her early-stage biotech and AI investment insight, her involvement strengthens Dash Bio’s leadership perspective and access to resources.
Brett Wilson offers critical advisory support on go-to-market strategy and fundraising, leveraging Swift Ventures’ network to advance Dash Bio’s customer acquisition and growth goals in the life sciences. His guidance has helped Dash Bio refine its business development efforts and fundraising outcomes.
Brett Wilson is a General Partner at Swift Ventures, with an MBA from Stanford University and a BS in Chemical Engineering from MIT. Previously a product manager at Genentech, he delivers biotech venture expertise and operational insight to Dash Bio leadership.
Dilpreet Singh leads Dash Bio’s engineering teams, overseeing design and deployment of lab automation hardware and software. He has been instrumental in ensuring reliability and scalability of the company’s automation systems, enabling fast, high-quality clinical bioanalysis.
Dilpreet Singh’s prior roles include Senior Engineering Manager at Thermo Fisher Scientific. He holds an MS in Mechanical Engineering from Stanford and a BS from the University of Michigan, specializing in laboratory instrumentation and automation technologies.
Priya Natarajan defines the product vision and manages the roadmaps for Dash Bio’s platform, driving feature development in line with customer feedback and market trends. She ensures the product suite meets evolving needs for accuracy, speed, and workflow integration in bioanalysis.
Prior to joining Dash Bio, Priya Natarajan served as Director of Product Management at Benchling. She earned her MBA from Harvard Business School and her BA in Biology from UCLA, building a career focused on life science software product management.
James Chen manages Dash Bio’s finance operations, leading budgeting, financial planning, and fundraising activities. He played a central role in securing the company’s seed funding and establishing financial processes to support rapid growth.
James Chen previously served as Finance Director at Moderna. A CPA with an MBA from the Wharton School and a BS in Accounting from the University of Texas at Austin, he brings tested finance leadership to Dash Bio management.
Olga Seltser heads up Dash Bio’s marketing strategy and external communications, elevating brand awareness, investor relations, and thought leadership in the biotech sector. Olga Seltser has expanded Dash Bio’s visibility through targeted media campaigns and industry conferences.
Olga Seltser was previously Marketing Director at Ginkgo Bioworks. She holds an MS in Communications from Northwestern University and a BA in Biochemistry from University of Chicago, combining biotech sector insight with advanced marketing expertise.
David Wilk directs Dash Bio’s sample logistics and processing operations, implementing comprehensive quality control and optimizing lab workflows to uphold GLP standards. His efforts ensure Dash Bio’s labs meet industry benchmarks for reliability and throughput.
David Wilk was Operations Manager at LabCorp and holds an MS in Laboratory Science from Johns Hopkins and a BS in Biology from University of Maryland. With deep expertise in clinical lab operations and regulatory compliance, he is a vital part of Dash Bio’s management team.
Dash Bio’s leadership team fuses expertise from biotechnology, AI, laboratory automation, and commercialization to drive rapid company growth and innovation. With founders experienced in executive and operational roles at Moderna and RootPath, and key management hailing from leading biotech and venture firms, the Dash Bio executives exemplify depth and versatility. Supported by strategic investors, the company has a lean, agile structure that promotes direct collaboration across engineering, product, finance, and operations.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the Dash Bio leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.